Literature DB >> 15735804

High glucose rapidly activates the nitric oxide/cyclic nucleotide pathway in human platelets via an osmotic mechanism.

Paola Massucco1, Luigi Mattiello, Isabella Russo, Monica Traversa, Gabriella Doronzo, Giovanni Anfossi, Mariella Trovati.   

Abstract

The aim was to evaluate whether high glucose influences the nitric oxide (NO)/cyclic nucleotide pathway in human platelets via osmotic stress and to clarify the role of protein kinase C (PKC) in this phenomenon. The study was carried out on 33 healthy lean male volunteers, aged 28.3+/-1.3 years. NO synthesis was detected as L-citrulline production after L-arginine incubation in platelets incubated for 6 min with 22.0 mM D-glucose and iso-osmolar concentrations of mannitol, L-glucose and fructose. To evaluate the influence of PKC, experiments with D-glucose and mannitol were repeated in the presence of the PKC-beta selective inhibitor LY379196, and NO synthesis was detected after a 6-min incubation with phorbol 12-myristate 13-acetate (PMA), a non-selective PKC activator. Platelet content of guanosine-3',5'-cyclic monophosphate (cGMP) and adenosine-3',5'-cyclic monophosphate (cAMP) was measured by radioimmunoassay in platelets incubated with iso-osmolar concentrations of D-glucose, mannitol, L-glucose and fructose. NO-dependence of cyclic nucleotide enhancements was evaluated by inhibiting NO synthase and guanylate cyclase. Platelet aggregation to ADP and collagen was evaluated in Platelet-Rich Plasma (PRP) in the presence of a 6-min incubation with D-glucose and mannitol, both without and with LY379196 and the guanylate cyclase inhibitor (H-[1,2,4]Oxadiazolo [4,3-a]quinoxaline-1-one)(ODQ). Iso-osmolar concentrations of D-glucose, mannitol, L-glucose and fructose, and PMA increased NO production (p=0.0001). Effects of D-glucose and mannitol were blunted by LY379196. D-glucose and mannitol enhanced platelet cGMP and cAMP (p=0.0001) with a mechanism blunted by NO synthase and guanylate-cyclase inhibition, but did not modify platelet aggregation. In conclusion, glucose activates the NO/cyclic nucleotide pathway in human platelets with an osmotic mechanism mediated by PKC-beta.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735804     DOI: 10.1160/TH04-06-0375

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Impact of impaired glucose tolerance on clopidogrel response in patients with coronary artery disease.

Authors:  Masafumi Ueno; Kosuke Fujita; Hiroyuki Yamamoto; Tomoyuki Ikeda; Tatsuya Suga; Kenji Yamaji; Shinichiro Ikuta; Kazuhiro Kobuke; Yoshitaka Iwanaga; Dominick J Angiolillo; Shunichi Miyazaki
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

2.  Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes.

Authors:  Galia Spectre; Claes-Göran Östenson; Nailin Li; Paul Hjemdahl
Journal:  Diabetes       Date:  2012-06-11       Impact factor: 9.461

Review 3.  Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.

Authors:  William B Hillegass; Brigitta C Brott; James C Dobbs; Silvio E Papapietro; Vijay K Misra; Gilbert J Zoghbi
Journal:  Vasc Health Risk Manag       Date:  2011-07-18

4.  Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus.

Authors:  Ornella Bosco; Barbara Vizio; Gabriella Gruden; Martina Schiavello; Bartolomeo Lorenzati; Paolo Cavallo-Perin; Isabella Russo; Giuseppe Montrucchio; Enrico Lupia
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

5.  High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets.

Authors:  Isabella Russo; Michela Viretto; Cristina Barale; Luigi Mattiello; Gabriella Doronzo; Andrea Pagliarino; Franco Cavalot; Mariella Trovati; Giovanni Anfossi
Journal:  Diabetes       Date:  2012-07-26       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.